These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 11920768)

  • 1. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: theoretical predictions with an oscillating diffusion coefficient model.
    Rohr UD; Saeger-Lorenz K
    J Pharm Sci; 2002 Mar; 91(3):822-44. PubMed ID: 11920768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results.
    Rohr UD; Saeger-Lorenz K
    J Pharm Sci; 2002 Mar; 91(3):810-21. PubMed ID: 11920767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
    Rohr UD; Ehrly AM; Kuhl H
    Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
    Rohr UD; Volko CD; Schindler AE
    Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
    Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
    Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
    Reginster JY; Donazzolo Y; Brion N; Lins R
    Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model analysis of flux enhancement across hairless mouse skin induced by chemical permeation enhancers.
    He N; Warner KS; Higuchi WI; Li SK
    Int J Pharm; 2005 Jun; 297(1-2):9-21. PubMed ID: 15907593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet.
    Järvinen A; Nykänen S; Paasiniemi L
    Maturitas; 1999 Jun; 32(2):103-13. PubMed ID: 10465378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
    de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
    Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data.
    Gavaler JS
    J Womens Health (Larchmt); 2003 Oct; 12(8):757-68. PubMed ID: 14588126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream.
    Saeheng S; Nosoongnoen W; Varothai S; Sathirakul K
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1372-7. PubMed ID: 23057672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
    Järvinen A; Bäckström A; Elfström C; Viitanen A
    Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations.
    Harrison LI; Zurth C; Gunther C; Karara AH; Melikian A; Lipp R
    Drug Dev Ind Pharm; 2007 Apr; 33(4):373-80. PubMed ID: 17523002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
    Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
    Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
    Rohr UD; Nauert C; Ehrly AM
    Zentralbl Gynakol; 1995; 117(10):531-9. PubMed ID: 7491836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
    Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
    Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
    Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
    Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.